Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease".

Vali, Yasaman; Anstee, Quentin M; Bossuyt, Patrick M

Vali, Yasaman; Anstee, Quentin M; Bossuyt, Patrick M.

Afiliação

Vali Y; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, The Netherlands. Electronic address: y.vali@amsterdamumc.nl.
Anstee QM; The Newcastle Liver Research Group, Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Bossuyt PM; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, The Netherlands.

J Hepatol ; 73(6): 1582-1583, 2020 12.

Article em En | MEDLINE | ID: mdl-32951911

Assuntos

Hepatopatia Gordurosa não Alcoólica; Fibrose; Humanos; Cirrose Hepática/diagnóstico; Testes de Função Hepática; Hepatopatia Gordurosa não Alcoólica/diagnóstico; Hepatopatia Gordurosa não Alcoólica/terapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google